Celyad Oncology S.A.
CYAD
Κατάταξη σε μετοχές
#31769
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Τιμή μετοχής
$0.24434797
Κεφαλαιοποίηση
$11.55M
Αλλαγή (1 ημέρα)
-9.25%
Αλλαγή (1 έτος)
-15.84%
Χώρα
BE
Εμπόριο Celyad Oncology S.A. (CYAD)
Κατηγορία
Healthcare
Κεφαλαιοποίηση αγοράς του Celyad Oncology S.A.(CYAD)
Κεφαλαιοποίηση: $11.55M
Μέχρι το October 2026, η Celyad Oncology S.A. έχει χρηματιστηριακή αξία $11.55M. Αυτό καθιστά τη Celyad Oncology S.A. την 31769th πιο πολύτιμη εταιρεία στον κόσμο βάσει της κεφαλαιοποίησης σύμφωνα με τα δεδομένα μας. Η χρηματιστηριακή κεφαλαιοποίηση είναι η συνολική αγοραία αξία των μετοχών μιας εισηγμένης εταιρείας και χρησιμοποιείται συνήθως για να προσδιοριστεί η αξία μιας εταιρείας.
Ιστορικό κεφαλαιοποίησης αγοράς της Celyad Oncology S.A. από 2014 έως 2026
CYAD σε σύγκριση με τα 5 πιο δημοφιλή stocks
| Η τιμή για CYAD | Το περιουσιακό στοιχείο B | Η κεφαλαιοποίηση αγοράς του B | Αποτελέσματα | |
|---|---|---|---|---|
$126,781
$21.57M
|
$5.252T | +24,347,042.51% | ||
|
$120,721
$21.57M
|
$5.001T | +23,183,193.77% | ||
|
$100,804
$21.57M
|
$4.176T | +19,358,356.39% | ||
|
$95,780.89
$21.57M
|
$3.968T | +18,393,758.07% | ||
|
$68,481.83
$21.57M
|
$2.837T | +13,151,219.00% |
